The role of noradrenaline and selective noradrenaline reuptake inhibition in depression

European Neuropsychopharmacology

Volumn 12, Issue 5, 2002, Pages 461-475

  Brunello, N ^a,b   Mendlewicz, J ^c   Kasper, S ^d   Leonard, B ^b   Montgomery, S ^b   Nelson, J Craig ^a   Paykel, E ^b   Versiani, M ^a   Racagni, G ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Catecholamines; Depression; Efficacy; Melancholia; Selective noradrenaline reuptake inhibition; Tolerability

Indexed keywords

ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMITRIPTYLINE; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE DERIVATIVE; CITALOPRAM; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; MUSCARINIC M1 RECEPTOR; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TYROSINE 3 MONOOXYGENASE; UNINDEXED DRUG; VENLAFAXINE;

ARTICLE; BINDING ASSAY; CARDIOTOXICITY; CAUSE OF DEATH; CHROMOSOME 12; CLINICAL TRIAL; DEPRESSION; DISSOCIATION CONSTANT; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; GENETIC LINKAGE; HEART ARRHYTHMIA; HUMAN; LICENSING; NEUROBIOLOGY; NEUROPHYSIOLOGY; NONHUMAN; ORTHOSTATIC HYPERTENSION; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR AFFINITY; RECEPTOR DENSITY; SIDE EFFECT; SOCIAL STATUS; SUICIDE ATTEMPT; TREATMENT OUTCOME; URINE RETENTION; VISUAL IMPAIRMENT; X CHROMOSOME; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; CATECHOL O-METHYLTRANSFERASE; DEPRESSION; HUMANS; IMIPRAMINE; MONOAMINE OXIDASE; MORPHOLINES; NOREPINEPHRINE; RECEPTORS, ADRENERGIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 0036787072     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00057-3     Document Type: Article

References (128)

1. Åberg A. Controlled crossover study of a 5-HT uptake inhibiting and an NA uptake inhibiting antidepressant. Acta Psychiatr. Scand. 63:(Suppl. 290):1981;244-255.
2. Amsterdam J.D., Maislin G., Potter L. Fluoxetine efficacy in treatment resistant depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 18:1994;243-261.
3. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 8:1994;238-249.
4. Andreoli V., Caillard M.D., Deo R.S., Rybakowski J.K., Versiani M. Reboxetine, a new selective noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J. Clin. Psychopharmacol. 22:2002;393-399.
5. Ban T.A., Gaszner P., Aguglia E., Batista R., Castillo A., Lipcsey A., Macher J.P., Torres-Ruiz A. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations. Hum. Psychopharmacol. 13:1998;S29-S39.
6. 2-adrenoceptors. Br. J. Pharmacol. 92:1987;827-834.
7. Berzewski H., Van Moffaert M., Gagiano C.A. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur. Neuropsychopharmacol. 7:(Suppl 1):1998;S37-S47.
8. Blier P., de Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7:1987;24S-35S.
9. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
10. Bosc M. Assessment of social functioning in depression. Comp. Psychiatry. 41:2000;63-69.
11. Bosc M., Dubini A., Polin V. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. Eur. Neuropsychopharmacol. 7:(Suppl. 1):1997;S57-S70.
12. Bowden C.L., Schatzberg A.F., Rosenbaum A., Contreras S.A., Samson J.A., Dessain E., Sayler M. Fluoxetine and desipramine in major depressive disorder. J. Clin. Psychopharmacol. 13:1993;305-310.
13. Byerley W., Hoff M., Holik J., Coon H. A linkage study with D5 dopamine and alpha 2C-adrenergic receptor genes in six multiplex bipolar pedigrees. Psychiatr. Genet. 4:1994;121-124.
14. 2a-adrenoceptor agonist binding sites in brains of depressed suicide victims. J. Neurochem. 70:1998;1114-1123.
15. Charney D.S., Heninger G.R., Sternberg D.E., Redmond D.E., Leckman J.F., Maas J.W., Roth R.H. Presynaptic adrenergic receptor sensitivity in depression. Arch. Gen. Psychiatry. 38:1981;1334-1340.
16. Clerc G.E., Ruimy P., Verdeau-Paillès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int. Clin. Psychopharmacol. 9:1994;139-143.
17. Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 114:1994;559-565.
18. Danish University Antidepressant Group . Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 90:1986;131-138.
19. Danish University Antidepressant Group . Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 18:1990;289-299.
20. Danish University Antidepressant Group . Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord. 28:1993;105-116.
21. de Jonghe F., Swinkels J., Tuynman-Qua H. A randomized double-blind study of fluvoxamine and maprotiline in the treatment of depression. Pharmacopsychiatry. 24:1991;G2-G7.
22. de Jonghe F., Swinkels J., Tuynman-Qua H. Randomized double-blind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry. 24:1991;21-27.
23. Delgado P., Moreno F. Antidepressants and the brain. Int. Clin. Psychopharmacol. 14:(Suppl. 1):1999;S9-S16.
24. Delgado P.L., Charney D.S., Heninger G.R. Efficacy of fluvoxamine in treatment-refractory depression. J. Affect. Disord. 15:1988;55-60.
25. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Arch. Gen. Psychiatry. 47:1990;411-418.
26. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Aghajanian G.K., Heninger G.R., Charney D.S. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch. Gen. Psychiatry. 51:1994;865-874.
27. Delgado P.L., Moreno F.A., Potter R., Gelenberg A.J. Norepinephrine and serotonin in antidepressant action: evidence from neurotransmitter depletion studies. Briley M., Antidepressant Therapy at the Dawn of the Third Millennium. 1997;140-161 Martin Dunitz, London.
28. de Montigny C., Aghajanian G.K. Tricyclic antidepressants long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science. 202:1978;1303-1306.
29. De Paermentier F., Cheetham S.C., Crompton M.R., Katona C.L.E., Horton R.W. Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res. 525:1990;71-77.
30. Dierick M., Ravizza L., Realini R., Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog. Neuropsychopharmacol. Biol. Psychiatry. 20:1996;57-71.
31. Dubini A., Bosc M., Polin V. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. J. Psychopharmacol. 11:(Suppl. 4):1997;S17-S23.
32. Fabre L.F., Scharf M.B., Itil T.M. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J. Clin. Psychiatry. 52:(Suppl.):1991;62-67.
33. Fahy T.J., O'Rourke D., Brophy J., Schazmann W., Sciascia S. Clomipramine and lofepramine in DSM-III-R panic disorder: a placebo controlled trail. J. Affect. Disord. 25:1992;63-76.
34. Fawcett J., Maas J.W. Depression and MHPG excretion. Arch. Gen. Psychiatry. 26:1972;246-251.
35. Feighner J.P., Boyer W.F. Selective Serotonin Reuptake Inhibitors. 1991;Wiley, New York.
36. Frazer A. Antidepressants. J. Clin. Psychiatry. 58:(Suppl. 6):1997;9-25.
37. Furlong R.A., Rubinsztein J.S., Ho L., Walsh C., Coleman T.A., Muir W.J., Paykel E.S., Blackwood D.H.R., Rubinsztein D.C. Analysis and meta-analysis of two polymorphisms within the tyrosine hydroxylase gene in bipolar and unipolar affective disorders. Am. J. Med. Genet. 5:1999;88-94.
38. 2 receptor-mediated head-twitch behaviour following antidepressant treatment to mice. Br. J. Pharmacol. 83:1984;235-242.
39. Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E.R. The economic burden of depression in 1990. J. Clin. Psychiatry. 54:1993;405-418.
40. Guelfi J.D., White C., Hackett D., Guichoux J.Y., Magni G. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J. Clin. Psychiatry. 56:1995;450-458.
41. Gutierrez B., Bertranpetit J., Guillamat R., Valles V., Arranz M.J., Kerwin R., Fananas L. Association analysis of the catechol-O-methyltransferase gene and bipolar affective disorder. Am. J. Psychiatry. 154:1997;113-115.
42. Hadley D., Hoff M., Jolik J., Reimherr F., Wender P., Coon H., Byerley W. Manic depression and the norepinephrine transporter gene. Hum. Hered. 45:1995;165-168.
43. Halper J.P., Mann J.J. Cardiovascular effects of antidepressant medications. Br. J. Psychiatry. 153:(Suppl. 3):1988;87-98.
44. Heal D.J., Bristow L.M., Hurst E.M., Elliott J.M., Buckett W.R. Sex-related differences in central adrenergic function and responsiveness to repeated administration of desipramine or electroconvulsive shock. Br. J. Pharmacol. 97:1989;111-118.
45. Hirschfeld R.M.A., Montgomery S.A., Keller M.B., Siegfried K., Schatzberg A.F., Moller H.-J., Healy D., Baldwin D., Humble M., Versiani M., Montenegro R., Bourgeois M. Social functioning in depression: a review. J. Clin. Psychiatry. 61:1998;268-275.
46. Jann M.W., Kurtz N.M. Treatment of panic and phobic disorders. Clin. Pharm. 6:1987;947-962.
47. Kalus O., Asnis G.N., Rubinson E., Kahn R., Harkavy Friedman J.M., Iqbal N., Grosz D., van Praag H., Cahn W. Desipramine treatment in panic disorder. J. Affect. Disord. 21:1991;239-244.
48. Kasper S. From symptoms to social functioning: differential effects of antidepressant therapy. Int. Clin. Psychopharmacol. 14:(Suppl. 1):1999;S27-S31.
49. Kasper S., Praschak-Rieder N., Tauscher J., Wolf R. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf. 17:1997;251-264.
50. Katona C., Bercoff E., Chiu E., Tack P., Versiani M., Woelk H. Reboxetine versus imipramine in the treatment of elderly depressed patients with depressive disorders: a double-blind randomised trial. J. Affect. Disord. 55:1999;203-213.
51. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 51:1994;8-19.
52. Kessler R.C., Rubinow D.R., Holmes C., et al. The epidemiology of DSM-III-R bipolar disorder in a general population survey. Psychol. Med. 27:1997;1079-1089.
53. Kind P., Sorensen J. The costs of depression. Int. Clin. Psychopharmacol. 7:1993;191-195.
54. Klein D.F. Endogenomorphic depression. Arch. Gen. Psychiatry. 31:1974;447-454.
55. s-α subunit gene in nine Australian pedigrees. J. Affect. Disord. 32:1994;187-195.
56. Leonard B.E. The role of noradrenaline in depression: a review. J. Psychopharmacol. 11:(Suppl.):1997;S39-S47.
57. Leonard B.E. Noradrenaline in basic models of depression. Eur. Neuropsychopharmacol. 7:(Suppl. 1):1997;S11-S16.
58. Lépine J.-P., Gastpar M., Mendlewicz J., Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychopharmacol. 12:1997;19-29.
59. Li T., Vallada H., Curtis D., Arranz M., Xu K., Cai G., Deng H., Liu J., Murray R., Liu X., Collier D.A. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics. 7:1997;349-353.
60. Lim L.C.C., Powell J., Sham P., Castle D., Hunt N., Murray R., Gill M. Evidence for a genetic association between alleles of monoamine oxidase A gene and bipolar affective disorder. Am. J. Med. Genet. 60:1995;325-331.
61. Lopez-Ibor J., Guelfi J.D., Pletan Y., Tournoux A., Prost J.F. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int. Clin. Psychopharmacol. 11:1996;41-46.
62. Lydiard B.R., Morton W.A., Emmanuel N.P., Zealberg J.J., Laraia M.T., Stuart G.W., O'Neill P.M., Ballenger J.C. Preliminary report: placebo-controlled double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol. Bull. 29:1993;183-188.
63. Maas J.W., Fawcett J., Dekirmenjian H. 3-methoxy-4-hydroxy phenylglycol (MHPG) excretion in depressive states. A pilot study. Arch. Gen. Psychiatry. 19:1968;129-134.
64. Maas J.W., Kocsis J.H., Bowden C.L., Davis J.M., Redmon D.E., Hanin I., Robins E. Pre-treatment neurotransmitter metabolites and response to imipramine or amitriptyline treatment. Psychol. Med. 12:1982;37-43.
65. Mann J.J., Stanely M., McBride P.A., McEwen B.S. Increased serotonin 2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. Arch. Gen. Pscyhiatry. 43:1986;954-959.
66. Massana J. Reboxetine versus fluoxetine: an overview of efficacy and tolerability. J. Clin. Psychiatry. 59:(Suppl. 14):1998;8-10.
67. Massana J., Möller H.J., Burrows G.D., Montenegro R.M. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int. Clin. Psychopharmacol. 14:1999;73-80.
68. McEntee W.J., Coffey C.J., Bondareff W.A., 1995. Double-blind comparison of sertraline and nortriptyline in the treatment of depressed geriatric outpatients. Proceedings of the 148th Annual Meeting of the American Psychiatry Association. Miami, Florida, USA.
69. McGrath P.J., Stewart J.W., Nunes E.V., Ocepek-Welikson K., Rabkin J.G., Quitkin F.M., Klein D.F. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am. J. Psychiatry. 150:1993;118-123.
70. 2-Adrenoceptors in the brain of suicide victims: increased receptor density associated with major depression. Biol. Psychiatry. 31:1992;471-490.
71. Mendlewicz J. Predicting response: serotonin reuptake inhibition. Int. Clin. Psychopharmacol. 14:(Suppl. 1):1999;S17-S20.
72. Miller H.L., Delgado P.L., Salomon R.M., Berman R., Krystal J.H., Heninger G.R., Charney D.S. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch. Gen. Psychiatry. 53:1996;117-128.
73. Montgomery S.A. Suicide and antidepressants. Drugs. 43:(Suppl. 2):1992;24-31.
74. Montgomery S.A. Reboxetine: additional benefits to the depressed patient. J. Psychopharmacol. 11:(Suppl. 4):1997;S9-S15.
75. Montgomery S.A. The efficacy and safety of reboxetine, a novel selective noradrenaline reuptake inhibitor, in the treatment of depression. Todays Ther. Trends. 17:1999;35-56.
76. Montgomery S.A. Managing the severely ill and long-term depressed. Int. J. Psychiatry Clin. Pract. 3:(Suppl. 1):1999;S13-S17.
77. Montgomery S.A., Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int. Clin. Psychopharmacol. 9:(Suppl. 4):1995;33-40.
78. Montgomery S.A., Lecrubier Y. Is severe depression a separate indication? Eur. Neuropsychopharmacol. 9:1999;259-264.
79. Montgomery S.A., Henry J., McDonald G., Dinan T., Lader M., Hindmarch I., Clare A., Nutt D. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int. Clin. Psychopharmacol. 9:1994;47-53.
80. Moon C. Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Br. J. Clin. Pract. 50:1996;240-244.
81. Mucci M. Reboxetine: a review of antidepressant tolerability. J. Psychopharmacol. 11:(Suppl 4):1997;S33-S37.
82. Murray C.J.L. The global burden of disease. Murray C.J.L Lopez A.D., Global Burden of Disease and Injury Series. Vol. 1:1996;20-903 The Harvard School of Public Health, Boston, MA.
83. Nelson J.C., Charney D.S. The symptoms of major depressive illness. Am. J. Psychiatry. 138:1981;1-13.
84. Neumeister A., Praschak-Rieder N., Hesselmann B., Vitouch O., Rauh M., Barocka A., Tauscher J., Kasper S. Effects of tryptophan depletion in drug-free depressed patients who responded to total sleep deprivation. Arch. Gen. Psychiatry. 55:1998;167-172.
85. Nierenberg A.A., Feighner J.P., Rudolph R., Cole J.O., Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J. Clin. Psychopharmacol. 14:1994;419-423.
86. Palvimaki E.-P., Laakso A., Kuoppamaki M., Syvalahti E., Hietala J. Up-regulation of beta-1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments. Psychopharmacology. 115:1994;543-546.
87. Parker G., Hadzi-Pavlovic D., Wilhelm K., Hickie I., Brodaty H., Boyce P., Mitchell P., Eyers K. Defining melancholia: properties of a refined sign-based measure. Br. J. Psychiatry. 164:1994;316-326.
88. Parsian A., Todd R.D. Genetic association between monoamine oxidase and manic-depressive illness: comparison of relative risk and haplotype relative risk data. Am. J. Med. Genet. 74:1997;475-479.
89. Paykel E.S., Weissman M.M. Social adjustment and depression. Arch. Gen. Psychiatry. 28:1973;659-663.
90. Paykel E.S., Weissman M., Prusoff B.A., Tonks C.M. Dimensions of social adjustment in depressed women. J. Nerv. Ment. Dis. 152:1971;158-172.
91. Paykel E.S. Social functioning and the depressed patient. Int. J. Psychiatry Clin. Pract. 3:1999;S9-11.
92. Poeldinger W., Haber H. Fluoxetine 40 mg versus maprotiline 75 mg in the treatment of outpatients with depressive disorders. Int. Clin. Psychopharmacol. 4:(Suppl. 1):1989;47-50.
93. Potter W.Z., Calil H.M., Extein I., Gold P.W., Wehr T.A., Goodwin F.K. Specific norepinephrine and serotonin uptake inhibitors in man: a crossover study with pharmacokinetic, biochemical, neuroendocrine and behavioral parameters. Acta Psychiatr. Scand. 63:(Suppl. 290):1981;152-165.
94. Preskorn S.H. Antidepressant drug selection: criteria and options. J. Clin. Psychiatry. 55:(Suppl. A):1994;6-22.
95. Puzynski S., Rode A., Bidzinski A., Mrozek S., Zaluska M. Failure to correlate urinary MHPG with clinical response to amitriptyline. Acta Psychiatr. Scand. 69:1984;117-120.
96. Racagni G., Brunello N. Physiology to functionality: the brain and neurotransmitter activity. Int. Clin. Psychopharmacol. 14:(Suppl. 1):1999;S3-S7.
97. Redmond D.E. New and old evidence for the involvement of a brain norepinephrine system in anxiety. Phenomenology and Treatment of Anxiety. 1979;153-203 Spectrum Publications, New York.
98. Robertson M.M., Abou-Saleh M.T., Harrison D.A., Nairac B.L., Edwards D.R.L., Lock T., Burns R.A., Katona C.L.E. A double-blind controlled comparison of fluoxetine and lofepramine in major depressive illness. J. Psychopharmacol. 8:1994;98-103.
99. Roose S.P., Glassman A.H., Attia E., Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry. 151:1994;1735-1739.
100. Roose S.P., Pollack B., Kennedy J., 1997. Paroxetine versus nortriptyline in ischemic disease. Proceedings of the 150th Annual Meeting of the American Psychiatric Association, San Diego, California, USA.
101. Roth D., Mattes J., Sheehan K.H., Sheehan D.V. A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 14:1990;929-939.
102. Rouillon F., Phillips R., Serrurier D., Ansart E., Gerard M.J. [Recurrence of unipolar depression and efficacy of maprotiline] French. Encephale. 15:1989;527-534.
103. Rubinsztein D.C., Leggo J., Goodburn S., Walsh C., Jain S., Paykel E.S. Genetic association between monoamine oxidase A microsatellite and RFLP alleles and bipolar affective disorder: analysis and meta-analysis. Hum. Mol. Genet. 5:1996;779-782.
104. Schatzberg A.F. Antidepressant effectiveness in severe depression and melancholia. J. Clin. Psychiatry. 60:(Suppl. 4):1999;14-22.
105. Schildkraut J.J. Catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry. 122:1965;509-522.
106. Schildkraut J.J. Norepinephrine metabolites as biochemical criteria for classifying depressive disorders and predicting responses to treatment: preliminary findings. Am. J. Psychiatry. 130:1973;695-699.
107. Smith K.A., Fairburn C.G., Cowen P.J. Relapse of depression after rapid depletion of tryptophan. Lancet. 349:1997;915-919.
108. Souery D., Lipp O., Mahieu B., Mendlewicz J. Advances in the genetics of depression. Honig X., Ansseau Y., van Praag H., Depression; Neurobiological, Psychopathological and Therapeutic Advances. 1997;Wiley, New York.
109. Spyraki C., Fibiger H.C. Functional evidence for subsensitivity of noradrenergic alpha 2 receptors after chronic desipramine treatment. Life Sci. 27:1980;1863-1867.
110. Stahl S.M. Mixed depression and anxiety: serotonin receptors as a common pharmacologic link. J. Clin. Psychiatry. 58:1997;20-26.
111. Stoudemire A., Frank R., Hedemark N., Kamlet M., Blazer D. The economic burden of depression. Gen. Hosp. Psychiatry. 8:1986;387-394.
112. Sulser F., Vetulani J., Mobley P.L. Mode of action of antidepressant drugs (commentary). Biochem. Pharmacol. 27:1978;257-261.
113. Thase M.E., Frank E., Mallinger A.G., Hamer T., Kupfer D.J. Treatment of imipramine-resistant recurrent depression. III: Efficacy of monoamine oxidase inhibitors. J. Clin. Psychiatry. 53:1992;5-11.
114. Thompson D., Buesching D., Gregor K.J., Oster G. Patterns of antidepressant use and their relation to costs of care. Am. J. Manage. Care. 2:1996;1239-1246.
115. Tweed D.L. Depression-related impairment: estimating concurrent and lingering effects. Psychol. Med. 23:1993;373-386.
116. Versiani M., Cassano G., Perugi G., Bnedetti A., Mastalli L., Nardi A., Savino M. Reboxetine, a selective noradrenaline reuptake inhibitor, is an effective and well tolerated treatment for panic disorder. J. Clin. Psychiatry. 63:2002;31-37.
117. Versiani M., Amin M., Chouinard G. A double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J. Clin. Psychopharmacol. 20:2000;28-34.
118. Versiani M., Mehilane L., Gaszner P., Arnaud-Castiglioni R. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J. Clin. Psychiatry. 60:1999;400-406.
119. Vetulani J., Stawarz R.J., Dingell J.V., Sulser F. A possible common mechanism of action of antidepressant treatments. Naunyn Schmiedeberg's Arch. Pharmacol. 293:1976;109-114.
120. Vetulani J., Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature. 257:1975;495-496.
121. Volz H.-P., Faltus F., Magyar I., Möller H.-J. Brofaromine in treatment-resistant depressed patients: a comparative trial versus tranylcypromine. J. Affect. Disord. 30:1994;209-217.
122. Weissman M.M., Paykel E.S. The Depressed Woman: a Study of Social Relationships. 1974;University of Chicago, Chicago, IL.
123. Wells K.B., Stewart A., Hays R.D., Burnam A., Rogers W., Daniels M., Berry S., Greenfield S., Ware J. The functioning and well-being of depressed patients. J. Am. Med. Assoc. 262:1989;914-919.
124. Wheatley D.P., van Moffaert M., Timmerman L., Kremer C.M.E. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J. Clin. Psychiatry. 59:1998;306-312.
125. White K., Wykoff W., Tynes L.L., Schneider L., Zemansky M. Fluvoxamine in the treatment of tricyclic-resistant depression. Psychiatr. J. Univ. Ott. 15:1990;156-158.
126. Wittchen H.-U., Knauper B., Kessler R.C. Lifetime risk of depression. Br. J. Psychiatry. 165:1994;16-22.
127. Wong E.H.F., Sonders M.S., Amara S.G., Tinholt P.M., Piercey M.F.P., Hoffmann W.P., Hyslop D.K., Franklin S., Porsolt R.D., Bonsignori A., Carfagna N., McArthur R.A. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol. Psychiatry. 47:2000;818-829.
128. Zanko M., Beigon A., 1983. Increased adrenergic receptor binding in human frontal cortex of suicide victims. 13th Annual Meeting of the Society for Neuroscience, Abstract No. 210.5.